ABIVAX, a leading European, clinical stage biopharmaceutical company developing and commercializing anti-viral compounds and human vaccines, today announced that it has signed an agreement with The Finlay Institute, Havana, Cuba, that will allow it to commercialise vaccines against typhoid, meningococcus, and leptospirosis, in Asian and Latin American markets...

The information contained on the pages that follow is restricted and is not for release, publication, or distribution in or into the Australia, Canada, Japan or the United States.

The information contained herein is not an offer of securities for sale or a solicitation of an offer to purchase securities in the United States or to any U.S. person, as defined in Regulation S under the U.S. Securities Act of 1933, as amended (the “Securities Act”).

None of the information contained on the pages that follow nor any copy thereof may be taken or transmitted in or into the United States or distributed, directly or indirectly, in or into the United States. Failure to comply with this directive may result in a violation of the Securities Act.